MOBIA MEDICAL, INC. Research and Development Expense
MOBIA MEDICAL, INC. (MOBI) reported Research and Development Expense of $2.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- MOBIA MEDICAL, INC. research and development expense for the quarter ending 2026-06-30 was $2.28M, a 60.65% increase year-over-year.
- MOBIA MEDICAL, INC. research and development expense for the quarter ending 2026-03-31 was $1.69M, a 24.96% increase year-over-year.
- MOBIA MEDICAL, INC. research and development expense for the quarter ending 2025-06-30 was $1.42M.
- MOBIA MEDICAL, INC. research and development expense for the quarter ending 2025-03-31 was $1.35M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $2.28M 10-Q · filed 2026-08-11 | $3.97M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $1.69M 10-Q · filed 2026-06-04 | |
| 2025-06-30 | $1.42M 10-Q · filed 2026-08-11 | $2.77M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $1.35M 10-Q · filed 2026-06-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B |